Conversion to a 7-day regimen of transdermal buprenorphine (Butrans Transdermal System, Purdue Pharma) from a stable regimen of hydrocodone/acetaminophen (Vicodin, Abbott) can be successful in patients with osteoarthritic pain of the hip or knee, according to a study presented at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md.
Conversion to a 7-day regimen of transdermal buprenorphine (Butrans Transdermal System, Purdue Pharma) from a stable regimen of hydrocodone/acetaminophen (Vicodin, Abbott) can be successful in patients with osteoarthritic (OA) pain of the hip or knee, according to a study presented at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md.
According to this study, 84.3% of patients with OA pain of the knee or hip were successfully converted from a stable hydrocodone/acetaminophen regimen to a 7-day buprenorphine regimen. Patients who received treatment with buprenorphine maintained analgesia, function, and sleep quality. Patients rated buprenorphine positively. Conversion to a low initial dose of buprenorphine may improve overall tolerability.
For this randomized, double-blind, double-dummy, parallel-group study, 198 adult patients with OA receiving a stable dosage of hydrocodone/acetaminophen (15 mg/d to 30 mg/d) were switched to the nearest equivalent dosage of open-label hydrocodone/acetaminophen for 7 days. Patients were then stratified based on their dosage and randomly assigned to treatment with titratable transdermal buprenorphine (10 µg/h to 20 µg/h) or fixed-dose transdermal buprenorphine (20 µg/h). The primary efficacy variable was completion of the 14-day, double-blind phase.
In all, 167 patients completed the 14-day, double-blind phase, and 84.3% were successfully converted to the transdermal regimen. The average proportion of days with successful analgesia was 74%. Overall, 85% patients preferred transdermal buprenorphine to the oral hydrocodone/acetaminophen regimen.
Patients randomly assigned to the lower dose (10 µg) of buprenorphine experienced slightly better tolerability compared with patients who received the higher dose (20 µg). The overall incidence of adverse events was lower in patients treated with titratable buprenorphine (10 µg to 20 µg) than that in the fixed-dose (20 µg) treatment group (52% vs 62%, respectively).
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More